Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Rev. Pesqui. Fisioter ; 11(1): 211-217, Fev. 2021. ilus, tab
Article in English, Portuguese | LILACS | ID: biblio-1253387

ABSTRACT

INTRODUÇÃO: O uso de contraceptivos orais combinados (COC) trata-se de um fator de risco para a doença aterosclerótica por comprometer o perfil lipídico e inflamatório, podendo o exercício físico minimizar essas condições. OBJETIVO: Testar a hipótese de que exercício físico pode modificar o perfil lipídico e inflamatório de mulheres em uso COC. MÉTODOS: Protocolo de um estudo sequencial cruzado com mulheres de 20 e 30 anos, irregularmente ativas, em uso de COC há pelo menos 6 meses. Realizouse uma avaliação físico-clínica (AFC) nas participantes com medidas antropométricas, VO2máx. indireto e análise do perfil lipídico e inflamatório. Na sequência separou-se as participantes em 2 grupos: O grupo intervenção inicial (GII) que iniciou praticando exercícios intervalados de alta intensidade por 2 meses, e o grupo intervenção posterior (GIP), que seguiu irregularmente ativo pelo mesmo período. Em seguida o GII e o GIP alternariam suas condições por mais 2 meses, totalizando 4 meses de acompanhamento e 3 AFC, realizadas no início, após 2 meses e ao final do estudo. As informações colhidas foram divididas em 3 momentos: Momento inicial (MI), momento pós exercício (MPE) e pós inatividade (MPI).


INTRODUCTION: The use of combined oral contraceptives (COC) is a risk factor for atherosclerotic disease because it compromises the lipid and inflammatory profile, and physical exercise can minimize these conditions. OBJECTIVE: To test the hypothesis that high intensity interval physical exercise promotes changes in the lipid and inflammatory profile of women who are irregularly active using COC. METHODS: Protocol of a crosssectional study with women of 20 and 30 years, irregularly active, using COC for at least 6 months. A physicalclinical assessment (AFC) was performed on the participants with anthropometric measurements, VO2max. analysis and analysis of the lipid and inflammatory profile. Afterwards, the participants were divided into 2 groups: the initial intervention group (GII) that started practicing high intensity interval exercises for 2 months, and the posterior intervention group (GIP), which remained irregularly active for the same period. Then the GII and GIP would alternate their conditions for another 2 months, totaling 4 months of follow-up and 3 AFC, performed at the beginning, after 2 months and at the end of the study. The information collected was divided into 3 moments: Initial moment (MI), post-exercise moment (MPE) and post-inactivity (MPI).


Subject(s)
Contraceptives, Oral, Hormonal , Women , Risk Factors
2.
Arch. med ; 21(1): 215-224, 2021/01/03.
Article in Spanish | LILACS | ID: biblio-1148447

ABSTRACT

Objetivo: presentar el caso de una paciente con retención de productos de la concepción (RPC) después de aborto médico, tratada con anticonceptivos orales combinados (ACOC), y efectuar revisión de la literatura. Caso Clínico: paciente de 37 años, con sangrado genital escaso y leve dolor pélvico, quien tuvo aborto provocado con misoprostol cuatro días antes, acude sin signos de infección, con endometrio mixto de 18,5 mm. Durante seis semanas de seguimiento persiste sangrado y endometrio mixto engrosado, con disminución lenta de la gonadotrofina corionica humana (GCH); se sospecha RPC, se suministra ciclo de ACOC y al terminarlos expulsa completamente el tejido retenido. Metodología: búsqueda bibliográfica en bases de datos Google Scholar, Science Direct, RIMA, PubMed. Revisión de literatura: la RPC se presenta después de parto o aborto (más frecuente). Criterios diagnósticos: sangrado persistente, hallazgos ecográficos y medición de GCH. Diagnóstico diferencial: enfermedad trofoblastica gestacional y malformaciones arteriovenosas uterinas. Es factible el manejo conservador, con bajas tasas de infección o procedimientos quirúrgicos. Ante la evolución prolongada, presencia de signos de infección o hemorragia importante, se impone la evacuación quirúrgica, tradicionalmente con dilatación y legrado, y más recientemente resección histeroscópica. La bibliografía reciente sugiere el uso de ACOC como manejo médico. En nuestro caso, la paciente tomó un ciclo de ACOC y al terminarlos presentó expulsión de los restos retenidos. Conclusiones: el manejo conservador de la RPC con ACOC surge como una opción en casos seleccionados; son necesarios estudios controlados para definir su utilidad..Au


Objective: to report the case of a patient with retained products of conception (RPC) after a medical abortion, successfully treated with combined oral contraceptives (COCs), and to review the literature. Clinical case: a 37-year-old patient, with little genital bleeding and slight pelvic pain, who had had a misoprostol-induced abortion four days before consulting, she attended without signs of infection, with a thikened 18.5 mm mixed endometrium. After six weeks follow-up genital bleeding and thickened mixed endometrium persist, with a slow decrease in human chorionic gonadotropin (HCG), RPC is suspected, and a COC cycle is administered, when finished, she completely expelled the retained tissue. Methodology: Google Scholar, Science Direct, RIMA and PubMed databases were searched. Literature review: RPC occurs after delivery or abortion (more frequent), diagnostic criteria: persistent bleeding, ultrasound findings and HCG measurement; the differential diagnosis includes gestational trophoblastic disease and uterine arteriovenous malformations. Conservative management is feasible, with low rates of infection or surgical procedures, however, in case of prolonged evolution, evident signs of infection or significant bleeding, surgical evacuation is required, traditionally with dilation and curettage, and more recently hysteroscopic resection. Novel bibliography suggests the use of ACOC as medical management. In our case, the patient took a cycle of COC and at the end she expelled the retained remains. Conclusions: conservative management of RPC with COC arises as an option in selected cases, controlled trails are needed to define its usefulness..Au


Subject(s)
Pregnancy , Abortion, Incomplete , Misoprostol , Contraceptives, Oral, Hormonal
4.
Rev. argent. salud publica ; 7(29): 31-34, dic. 2016. tab
Article in Spanish | LILACS, BRISA | ID: biblio-869585

ABSTRACT

Esta evaluación de tecnología sanitaria compara un nuevo anovulatorio oral combinado con etinil estradiol 20µ más gestodeno 75µ, con el que contiene etinil estradiol 30µ más levonorgestrel 150µ, utilizado hasta ahora en el subsistema de salud pública de la provincia de Neuquén. De acuerdo a las evidencias halladas, en cuanto a equivalencia de eficacia y riesgos de seguridad –principalmente relativas al aumento significativo en el riesgo de presentar trombosis venosa y embolia pulmonar– se recomienda fuertementeno incorporarlo al vademécum provincial.


Subject(s)
Humans , Contraceptives, Oral, Combined , Progesterone Congeners , Pulmonary Embolism , Levonorgestrel , Venous Thrombosis
5.
Rev. cuba. farm ; 50(1)ene.-mar. 2016. graf
Article in English | LILACS, CUMED | ID: biblio-844875

ABSTRACT

Forty-one year old female admitted to the hospital because of symptoms and signs suggestive of pulmonary thromboembolism which was confirmed by CT angiography. There was no history of prior thromboembolic events, smoking, venous stasis or vascular lesion (negative lupus anticoagulant and anticardiolipins). The only documented hypercoagulability factor was the use of an oral contraceptive containing drospirenone and ethinylestradiol for the last year. The patient was treated with anticoagulants such as enoxaparin and she recovered without sequelae; she is currently under treatment with warfarin as an outpatient. It is known that the use of combined oral contraceptives in patients over 35 years old requires caution, largely due to higher risk of thromboembolic events associated with increased hepatic synthesis of several coagulation factors. Therefore, this case represents a potentially fatal and preventable severe adverse reaction(AU)


Mujer de 41 años que ingresa al hospital por cuadro clínico sugestivo de tromboembolismo pulmonar, el cual fue confirmado por AngioTAC. No había antecedentes de eventos tromboembólicos previos, tabaquismo, estasis venosa ni de lesión vascular (anticoagulante lúpico y anticardiolipinas negativo). Como único factor de hipercoagulabilidad que se documenta es el consumo de un anticonceptivo oral que contenía drospirenona y etinilestradiol desde un año atrás. La paciente fue anticoagulada con enoxaparina y se recuperó sin secuelas y actualmente se encuentra en manejo ambulatorio con warfarina. El uso de anticonceptivos orales en combinación se debe realizar con precaución en pacientes mayores de 35 años, en buena medida por el aumento del riesgo de eventos tromboembólicos asociado al incremento en la síntesis hepática de algunos factores de coagulación. Por lo tanto, éste representa un caso de reacción adversa severa, potencialmente fatal y prevenible(AU)


Subject(s)
Humans , Female , Pulmonary Embolism/drug therapy , Warfarin/therapeutic use , Contraceptives, Oral, Combined/adverse effects
6.
Femina ; 39(10)out. 2011.
Article in Portuguese | LILACS | ID: lil-641382

ABSTRACT

Denominam-se regimes estendidos em contracepção oral combinada a utilização de pílulas por mais de 28 dias sem pausa, visando a supressão da menstruação. Incluem o uso contínuo dos contraceptivos, bem como de regimes com intervalos trimestrais. Os questionamentos acerca da necessidade da menstruação, bem como dos intervalos mensais entre as usuárias de anticoncepcionais hormonais, motivou, nos últimos anos, o interesse crescente por regimes contraceptivos não convencionais. Nesse sentido, a conveniência e a melhora dos sintomas como cólicas, cefaleia e inchaço figuram entre as principais indicações dos regimes estendidos, além do possível efeito sobre doenças menstruais relacionadas. O propósito deste estudo foi identificar os principais aspectos referentes ao uso dos anticoncepcionais em regime estendido, com ênfase sobre as indicações, formulações disponíveis, padrão de sangramento, efeitos adversos e perfil metabólico


Extended regimens in combined oral contraception mean continuous administration, greater than 28 days of active hormone, in order to avoid menstruation. Extended regimens include some kind of contraception with no interval (as continuous) and with intervals every three months. Questions about the necessity of menstruation, as well as monthly intervals between hormonal contraceptive has motivated the growing interest in unconventional contraceptives regimens. Convenience and improved symptoms such as cramping, bloating and headache are among the main indications for extended regimens, in addition to the possible effect on menstrual-related diseases. The purpose of this study was to identify the main aspects regarding the use of contraceptives in extended regimens, with emphasis on indications, formulations available, bleeding patterns, adverse effects and metabolic profile


Subject(s)
Humans , Female , Contraception/methods , Contraception , Contraceptives, Oral, Combined/administration & dosage , Menstrual Cycle , Menstrual Cycle/metabolism , Drug Administration Schedule , Menstruation Disturbances/drug therapy , Menstruation , Metrorrhagia/chemically induced , Patient Satisfaction , Time Factors
7.
Article in English | IMSEAR | ID: sea-137718

ABSTRACT

A randomized double blind clinical trial was carried out at the Division of Family Planning, Siriraj Hospital in order to study the efficiency of low dose oral contraceptive pills, containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestel, for postponement of menstruation. Sixty hralthy women with previous regular menstruation were randomly assigned to one of two study groups. Thirty women in the control group received 10 capsules of a placebo and the other 30 women in the study group received 10 capsules that contained the oral contraceptives. The women in both groups began taking the in doses of one capsule per day for three days before the expected date of menstruation. The characteristics of both groups were comparable. The number of women who expected postponement of their menstruation were recorded together with the side-effects. The results showed that oral contraceptive pills taken three days before the expected date of menstruation could postpone menstruation significantly (27/30 vs 2/30, p< 0.05). The major side-effects were headache (10 percent) and nausea (13.3 percent).

8.
Article in English | IMSEAR | ID: sea-138096

ABSTRACT

The influence of combined oral contraceptives, namely, ethinyl estradiol (30 µg) and levonorgestrel (150 µg) was studied in nine cases of thyrotoxicosis divided into two groups: one group of htyrotoxic woman treated with propyl thiouracil (PTU) and another untreated group. The latter group of patients were than maintained on both PTU and the combined oral contraceptive pills; some cases were studied for 16-33 months. Before, during and after treatment, all patients were tested and confirmed by clinical examinations and thyroid function tests which were divided into two group: in vivo (24h 131/I uptake and T3-suppression test) and in vivo (total serum thyroxine (TT4), total T3 (TT3), T3 uptake (T3U), free thyroxine index (FTI) and thyrotropin (TSH). The results revealed that the values of TT4, TT3 and FTI were markedly high in the untreated group but these values decreased significantly (P<0.001) and remained within normal ranges after treatment with PTU and the contraceptive pills was initiated. Improved clinical symptoms and sings were also observed. However, the levels of TT4, TT3 and T3 uptake were elevated in the long-term treatments of both groups, but the FTI and TSH values were within normal limits, indicating that the values of FTI as well as TSH gave effective measurements of thyroid activity in evaluating the patients whose total thyroid hormones were abnormal because of altered TBG concentration and binding capacity. Therefore, our finding suggested that the prolonged use of combined oral contraceptive pills dose not interfere with medical treatment of thyrotoxic patients.

SELECTION OF CITATIONS
SEARCH DETAIL